Ligand Pharmaceuticals Inc LGND
The biggest changes in the 10-K filed Feb 27, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“Total revenue and income increased by $101.0 million, or 60%, to $268.1 million in 2025 compared to $167.1 million in 2024 primarily due to the $52.2 million increase in royalties and $39.4 million increase in contract revenue and income.”
Read it in the 10-K
“Contract revenue and income increased by $39.4 million, with the change primarily due to income from the Pelthos Transaction.”
Read it in the 10-K
Cash from operations
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +60.4%
“Total revenue and income increased by $101.0 million, or 60%, to $268.1 million in 2025 compared to $167.1 million in 2024 primarily due to the $52.2 million increase in royalties and $39.4 million increase in contract revenue and income.”
Read it in the FY 2025 10-K“Contract revenue and income increased by $39.4 million, with the change primarily due to income from the Pelthos Transaction.”
Read it in the FY 2025 10-K -
FY 2024 +27.3%
“Total revenue and other income increased by $35.8 million, or 27%, to $167.1 million in 2024 compared to $131.3 million in 2023 primarily due to the $23.8 million increase in royalties.”
Read it in the FY 2024 10-K“Contract revenue and other revenue increased by $9.5 million primarily due to milestone payments earned from Verona Pharma upon the approval and commercial launch of Ohtuvayre.”
Read it in the FY 2024 10-K
Operating margin
0 of 2 years explained-
FY 2025 +28.8 pts
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 -22.6 pts
The FY 2024 MD&A has no sentence that names a cause for this change.
Cash from operations
0 of 2 years explained-
FY 2025 -49.1%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +95.8%
The FY 2024 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.